The major indications for LTx included chronic obstructive pulmonary disease (COPD) (n = 5), cystic fibrosis (n = 11), alpha-1 antitrypsin deficiency (n = 9), pulmonary fibrosis (n = 7), pulmonary hypertension (n = 5), and other (n = 3). This evidence concerns the gene PSMA6 and pulmonary fibrosis.